Novel nebulizers and methods are provided for a nebulizer including a dialable negative pressure threshold valve that actuates in response to different negative pressures corresponding to different negative pressure threshold settings of actuation of the valve to influence inhalation effort, aerosol entrainment, and aerosol delivery.

An atomizing nozzle structured particularly for nasal therapy. Preferred embodiments include a 2-piece atomizing nozzle structured to couple with luer-locking structure carried by a syringe. Such an atomizing nozzle includes a nasal stopper and a stem. A preferred nasal stopper includes a distal tip sized for insertion into a nostril of a human child, with a proximal shield portion being structured to resist over-insertion of a discharge orifice into the nostril. A nasal stopper desirably provides a centering function to urge the discharge orifice away from a nasal wall. One operable stem is structured to couple with the stopper and desirably carries unitary thread structure at a proximal end. A second operable stem is structured as a unitary part of the nasal stopper and also desirably carries unitary thread structure at a proximal end. Certain embodiments may also include spacer structure configured to reduce a dead volume inside the atomizing nozzle. Other embodiments may also include spacer structure configured to reduce dead volume inside a syringe that is coupled to the atomizing nozzle.

An atomizing nozzle structured particularly for nasal therapy. Preferred embodiments include a 2-piece atomizing nozzle structured to couple with luer-locking structure carried by a syringe. Such an atomizing nozzle includes a nasal stopper and a stem. A preferred nasal stopper includes a distal tip sized for insertion into a nostril of a human child, with a proximal shield portion being structured to resist over-insertion of a discharge orifice into the nostril. A nasal stopper desirably provides a centering function to urge the discharge orifice away from a nasal wall. One operable stem is structured to couple with the stopper and desirably carries unitary thread structure at a proximal end. A second operable stem is structured as a unitary part of the nasal stopper and also desirably carries unitary thread structure at a proximal end. Certain embodiments may also include spacer structure configured to reduce a dead volume inside the atomizing nozzle. Other embodiments may also include spacer structure configured to reduce dead volume inside a syringe that is coupled to the atomizing nozzle.

A venturi inhalation device is provided. The device has a tube defining an internal volume with a fine bore needle disposed at one end. The fine bore needle is in fluid communication with the internal volume of the tube such that medication stored therein can pass into the needle. The tube has a second end which can be sealed to contain the medication until the device is used. A hollow housing is sized and shaped to receive the tube in close tolerance, whereupon the tube being so received, an air-tight seal is formed. The housing also includes a venturi restriction, and when the tube is received by the first end of the housing, a distal end of the fine bore needle is placed within the venturi restriction. A mouthpiece is disposed on a second end of the housing enabling a user to inhale the medication in the tube.

The present invention relates to a liquid pharmaceutical formulation and a method for administering a pharmaceutical formulation by nebulizing the pharmaceutical formulation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) budesonide, olodaterol and tiotropium bromide; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) and a pharmacologically acceptable stabilizer, optionally including other pharmacologically acceptable additives.

A chest-supported nebulizer apparatus. The chest-supported nebulizer apparatus has a planar base that rests on the chest of a user. At least one lateral strap and a neck strap is removably securable from the planar base. The neck strap can encircle the neck of the user and is slidably adjustable to adjust the length of the neck strap. A receptacle is disposed in the planar base, wherein the receptacle can receive a central support therein. The central support is pivotally affixed to the receptacle, allowing a user to adjust the angle of the central support relative to the planar base. A support assembly is slidably affixed to the central support. The support assembly is sized to receive a nebulizer.

A chest-supported nebulizer apparatus. The chest-supported nebulizer apparatus has a planar base that rests on the chest of a user. At least one lateral strap and a neck strap is removably securable from the planar base. The neck strap can encircle the neck of the user and is slidably adjustable to adjust the length of the neck strap. A receptacle is disposed in the planar base, wherein the receptacle can receive a central support therein. The central support is pivotally affixed to the receptacle, allowing a user to adjust the angle of the central support relative to the planar base. A support assembly is slidably affixed to the central support. The support assembly is sized to receive a nebulizer.

The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) glycopyrrolate and indacaterol maleate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) a pharmacologically acceptable stabilizer.

An electronic vaping device is provided including a power supply portion comprising a power supply, an atomizer/liquid reservoir portion comprising a liquid reservoir storing a liquid, and an atomizer adapted to atomize the liquid stored in the liquid reservoir when operated by the power supply. The atomizer is adapted to float on the surface of the liquid in the liquid reservoir.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.